OrthoPediatrics Q2 revenue up 16%

Orthopediatrics

05/08/2025 21:32

Overview

OrthoPediatrics Q2 revenue rises 16% but misses analyst expectations, per LSEG data

Adjusted EBITDA for Q2 rises to $4.1 mln, missing estimates, per LSEG data

Company expands Specialty Bracing Division into new territories, including Ireland

Outlook

OrthoPediatrics raises full-year 2025 revenue guidance to $237 mln-$242 mln

Company reiterates full-year 2025 adjusted EBITDA of $15 mln-$17 mln

OrthoPediatrics expects positive free cash flow by Q4 2025

Company anticipates full-year free cash flow breakeven in 2026

Result Drivers

SCOLIOSIS GROWTH - Revenue from scoliosis products increased 35%, driven by Response and ApiFix system sales

TRAUMA & DEFORMITY - Revenue from trauma and deformity products rose 10%, supported by PNP Femur, PNP Tibia, DF2, and OPSB

OPSB EXPANSION - Expansion of Specialty Bracing Division into new territories, including Ireland, contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$61.10 mln
$61.40 mln (7 Analysts)
Q2 EPS
-$0.3
Q2 Net Income
-$7.10 mln
Q2 Adjusted EBITDA
Miss
$4.10 mln
$4.29 mln (6 Analysts)
Q2 Gross Margin
72.0%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OrthoPediatrics Corp is $37.00, about 44.5% above its August 4 closing price of $20.53

Press Release: ID:nGNX9jqCCL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)